Hormone receptor status-Positive (ER and/or PR) - Page 3 of 6 Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More

Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...

Read More

Using palbociclib alone or with other therapies in advanced ER+ breast cancer

Using palbociclib alone or with other therapies in advanced ER+ breast cancer

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

The optimal duration of hormone therapy for post menopausal patients with early breast cancer

The optimal duration of hormone therapy for post menopausal patients with early breast cancer

Posted by on Jan 15, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the benefits of taking letrozole for 2.5 years versus 5 years in post-menopausal patients with early stage breast cancer. This study found no benefit of five years extended therapy with letrozole compared to 2.5 years, after an initial five years of hormone therapy.  Some background Breast...

Read More

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer

Posted by on Dec 23, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to determine the effectiveness and safety of ribociclib (Kisqali) combined with a non-steroidal aromatase inhibitor in elderly patients with hormone receptor positive and HER-2 negative breast cancer. This study concluded that ribociclib improved progression free survival and was relatively safe to use...

Read More

Searching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.

Posted by on Oct 30, 2017 in Breast cancer | 0 comments

In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States.  The details...

Read More